From our very first day as a company to today, our exceptional team has sought to propel the very best scientific ideas beyond the bench all the way to the bedside, ensuring that life-changing therapies reach their full potential and get to patients in need.

We achieved this goal with APHEXDA® (motixafortide), the next-generation, best-in-class stem cell mobilization agent that we successfully shepherded from early clinical development through FDA approval and commercial launch in September 2023.

With the successful commercial out-licensing of APHEXDA® completed, BioLineRx has returned to its roots as a lean development company, but with much broader and deeper knowledge of what it takes to successfully develop a therapeutic agent. To that end, we have formed a joint venture to develop GLIX1, a first-in-class, oral small molecule that uniquely targets the DNA damage response in cancer cells. It has also demonstrated excellent blood-brain-barrier penetration.

While the lead indication is glioblastoma, GLIX1 has demonstrated compelling efficacy in other cancer models, and we are advancing pre-clinical activities in additional cancer indications, including in combination with established anti-cancer agents such as PARP inhibitors.

Under our collaboration with Columbia, which is jointly funded by both BioLineRx and Regeneron, a Phase 2b study in pancreatic ductal adenocarcinoma (PDAC) continues to advance. If successful, our PDAC program, which operates at minimal cost to the company, has the potential to meaningfully address the significant unmet need for this devastating disease.

We at BioLineRx are energized by the potential of both the GLIX1 and PDAC programs and are well-positioned to apply our deep experience and focused execution to advance these potential high-impact therapies through advanced clinical development.

Philip Serlin

Chief Executive Officer